“An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study”, J of Skin, vol. 3, p. S12, Nov. 2019, doi: 10.25251/skin.3.supp.12.